SCHEDULE: Valion Bio: 3i LP Adjusts Stake in Amendment 5 Filing

Valion Bio, Inc. has filed an amendment to its Schedule 13D, with 3i LP reporting a minor purchase of common stock and detailing its beneficial ownership structure.

Summary

• This filing is Amendment No. 5 to a Schedule 13D for Valion Bio, Inc. concerning its common stock.
• The filing details the beneficial ownership of several reporting persons: 3i, LP, Tumim Stone Capital, LLC, 3i Management LLC, and Maier J. Tarlow.
• As of August 24, 2026, the total outstanding shares of Valion Bio, Inc. common stock were 32,140,634.
• 3i, LP and 3i Management LLC beneficially own 3,334,139 shares, representing 9.9% of the class.
• This ownership includes 2,100,000 directly held shares and 1,234,139 shares issuable upon exercise of warrants, conversion of a convertible note, or conversion of Series B and Series C Convertible Preferred Stock, all subject to a 9.99% beneficial ownership limitation (Blocker).
• Maier J. Tarlow also beneficially owns 3,334,139 shares (9.9%) indirectly through the same instruments.
• Tumim Stone Capital, LLC reports 0.00% beneficial ownership.
• The filing includes a transaction on August 25, 2026, where 3i, LP purchased 132,702 shares at $0.1574 per share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative score due to the nature of the filing being an amendment to a Schedule 13D, indicating ongoing adjustments in beneficial ownership rather than a new strategic development. The disclosed transactions are minor in the context of the total shares outstanding.

Positives

• The filing provides clarity on the beneficial ownership structure of Valion Bio, Inc. by key entities and individuals.
• The disclosure confirms the total number of outstanding shares as of August 24, 2026, aiding in accurate percentage calculations.
• A specific purchase transaction by 3i, LP on August 25, 2026, is detailed, showing a minor increase in direct holdings.

Negatives

• The filing is an amendment to a previous filing, suggesting ongoing adjustments and potentially a lack of a definitive, stable ownership position.
• The beneficial ownership is heavily reliant on future conversions and warrant exercises, which are subject to limitations (Blockers), indicating potential hurdles to full ownership realization.
• Tumim Stone Capital, LLC reports no beneficial ownership, which could imply a reduced strategic interest or a different role.

Risks

• The beneficial ownership is capped by a 9.99% 'Blocker' provision, limiting the ability to acquire a larger stake through conversions or warrant exercises.
• The reliance on convertible notes and preferred stock introduces risks associated with the issuer's financial health and ability to meet conversion terms.
• The filing does not provide specific details on the 'New Transaction' beyond the purchase by 3i, LP, leaving room for interpretation regarding its strategic purpose.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. The future outlook for the reporting persons' stake is contingent on the exercise of warrants and conversion of convertible securities, subject to ownership limitations.

Management Comments

• The filing is signed by Maier J. Tarlow in various capacities, indicating his managerial role and oversight of the reporting entities.
• The 'Comment for Type of Reporting Person' sections for 3i, LP, 3i Management LLC, and Maier J. Tarlow all refer to the details provided in Item 5 regarding beneficial ownership and the 'Blocker' provisions.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common for significant investors acquiring more than 5% of a company's stock. Amendments indicate ongoing activity or changes in holdings. The structure of ownership through convertible instruments and warrants is typical in venture capital or activist investing scenarios, especially for smaller or development-stage companies.

Stakeholder Impact

• Shareholders: The filing provides transparency on significant ownership stakes and potential future changes, which can influence market perception.
• Management: The reporting persons' stake and potential influence may impact strategic decisions and board composition discussions.
• Creditors: The nature of the convertible note and preferred stock could be relevant to creditors assessing the company's capital structure and debt obligations.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership levels in Valion Bio, Inc.
• Further transactions or changes in holdings may lead to additional amendments to the Schedule 13D.
• The exercise of warrants and conversion of securities will be managed within the constraints of the 9.99% ownership limitation.

Key Dates

Keywords

Valion Bio, Schedule 13D, Beneficial Ownership, 3i LP, Convertible Note, Warrants, Preferred Stock, Amendment